Market Place
Sourcing Support
Revive Therapeutics Publishes Psilocybin Stroke Approach
12 Nov 2024 //
GLOBENEWSWIRE
Revive Therapeutics Updates Bucillamine Nerve Agent Exposure Study
31 Oct 2024 //
GLOBENEWSWIRE
Revive Therapeutics Provides Bucillamine Nerve Agent Study Update
31 Oct 2024 //
GLOBENEWSWIRE
Revive Focuses On Bucillamine For Infectious Diseases
18 Sep 2024 //
GLOBENEWSWIRE
Revive Therapeutics Updates On Bucillamine Research For Nerve Agents
28 Aug 2024 //
GLOBENEWSWIRE
Revive Therapeutics Updates On Bucillamine For Nerve Agent Exposure Study
02 Jul 2024 //
GLOBENEWSWIRE
Revive Therapeutics Updates On FDA Meeting For Long COVID Study
12 Jun 2024 //
GLOBENEWSWIRE
Revive Updates On FDA Meeting For Long COVID Diagnostic Product
10 Jun 2024 //
GLOBENEWSWIRE
Revive Requests FDA Meeting for Bucillamine Long COVID Study
23 Apr 2024 //
GLOBENEWSWIRE
Revive: FDA Meeting For Long COVID Diagnostic Test Accepted
18 Apr 2024 //
GLOBENEWSWIRE
Revive Provides Update on Psilocybin Study for Methamphetamine Use Disorder
02 Apr 2024 //
GLOBENEWSWIRE
Revive Submits Type C Meeting Request Package to FDA for trial of Bucillamine
27 Mar 2024 //
GLOBENEWSWIRE
Revive To Submit Type C Meeting Request with FDA for Bucillamine to Treat COVID
19 Mar 2024 //
GLOBENEWSWIRE
Revive Therapeutics Provides Corporate Update
12 Mar 2024 //
GLOBENEWSWIRE
Revive Announces Closing of the Second & Final Tranche of Its Private Placement
26 Feb 2024 //
GLOBENEWSWIRE
Revive Therapeutics Explores the Use of Bucillamine for Long COVID
01 Feb 2024 //
GLOBENEWSWIRE
Revive Announces Closing of the First Tranche of Its Private Placement
31 Jan 2024 //
GLOBENEWSWIRE
Revive Therapeutics Ltd. Announces Offering of Up to $3 Million
24 Jan 2024 //
GLOBENEWSWIRE
Revive Provides Update Evaluating Bucillamine for Nerve Agent Exposure
16 Jan 2024 //
GLOBENEWSWIRE
Revive Completes Development of Lyophilized Formulation of Bucillamine
10 Jan 2024 //
GLOBENEWSWIRE
Revive Therapeutics Collaborates with Attwill Medical Solutions
18 Dec 2023 //
GLOBENEWSWIRE
Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development
21 Nov 2023 //
GLOBENEWSWIRE
Revive Enters into Agreement with Defence R&D for Evaluating Bucillamine
17 Oct 2023 //
GLOBENEWSWIRE
Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development
11 Oct 2023 //
GLOBENEWSWIRE
Revive Therapeutics Announces Filing of Patent for Bucillamine
28 Jul 2023 //
GLOBENEWSWIRE
Revive Therapeutics` experimental COVID treatment fails in late-stage study
07 Jul 2023 //
REUTERS
Revive Announces Results of Ph3 Clinical Study for Bucillamine in of COVID-19
06 Jul 2023 //
GLOBENEWSWIRE
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine
30 May 2023 //
GLOBENEWSWIRE
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine
12 May 2023 //
GLOBENEWSWIRE
Revive kills off COVID trial after dip into data foresees flop
12 May 2023 //
FIERCE BIOTECH
Revive Announces Data Safety Monitoring Board Meeting Pha3 Study of Bucillamine
02 May 2023 //
GLOBENEWSWIRE
Revive Advances MDMA Transdermal Patch Development with Purchase of MDMA Supply
03 Apr 2023 //
GLOBENEWSWIRE
Revive Provides Update on Psilocybin Study for Methamphetamine Use Disorder
28 Mar 2023 //
GLOBENEWSWIRE
Revive Provides Phase 3 Study for Bucillamine in the Treatment of COVID-19
20 Mar 2023 //
GLOBENEWSWIRE
Revive Provides Update From Type C Meeting with FDA forfor Bucillamine
08 Mar 2023 //
GLOBENEWSWIRE
Phil McDermott Appointed co-CEO of REVIV a Global Leader in IV Therapy
10 Feb 2023 //
BUSINESSWIRE
PharmAla Named Exclusive MDMA Supplier to Revive Therapeutics
06 Feb 2023 //
GLOBENEWSWIRE
Revive Enters into Research Collaboration Agreement with PharmaTher
03 Feb 2023 //
GLOBENEWSWIRE
Revive Therapeutics Ltd. Closes $4.3 Million Offering
12 Jan 2023 //
GLOBENEWSWIRE
Revive Therapeutics Announces Publication Showing Bucillamine Potential Impact
09 Jan 2023 //
GLOBENEWSWIRE
Revive Therapeutics Announces Submission of Type C Meeting Request
22 Dec 2022 //
GLOBENEWSWIRE
Revive Therapeutics Ltd. Expands Life Offering to Quebec
15 Dec 2022 //
GLOBENEWSWIRE
Revive Therapeutics Ltd. Announces Offering of Up to $5 Million
30 Nov 2022 //
GLOBENEWSWIRE
Revive Announces Update for Meeting regarding PIII Study for Bucillamine
24 Nov 2022 //
GLOBENEWSWIRE
Revive Therapeutics Announces Finalization of Amended Phase 3 COVID-19 Study
15 Oct 2022 //
GLOBENEWSWIRE
Revive to submit revised protocol for Phase III Covid-19 oral drug trial
07 Oct 2022 //
CLINICALTRIALSARENA
Revive Therapeutics Provides Update on Pha3 Clinical Trial for Bucillamine
06 Oct 2022 //
GLOBENEWSWIRE
Revive Provides Update on the Psilocybin Clinical Study for Methamphetamine
16 Sep 2022 //
GLOBENEWSWIRE
Revive Therapeutics Announces Submission of Amended Phase 3
14 Sep 2022 //
GLOBENEWSWIRE
Revive Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
16 Aug 2022 //
GLOBENEWSWIRE
Revive Therapeutics Provides Update on PIII Trial for Bucillamine in COVID-19
25 Jul 2022 //
GLOBENEWSWIRE
Revive Therapeutics Provides Update on PIII Trial for Bucillamine in COVID-19
06 Jun 2022 //
GLOBENEWSWIRE
Revive Advances ILD Programs for Autoimmune Hepatitis and Liver Transplantation
31 May 2022 //
GLOBENEWSWIRE
Revive Therapeutics Provides Update on PIII Trial for Bucillamine in COVID-19
16 May 2022 //
GLOBENEWSWIRE
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine
25 Apr 2022 //
GLOBENEWSWIRE
Revive Tx to Publish Research Data with Bucillamine in COVID-19
18 Apr 2022 //
GLOBENEWSWIRE
HAVN Life Secures Purchase Order for Controlled Substance Sale
24 Feb 2022 //
GLOBENEWSWIRE
Revive Therapeutics Receives FDA ODD for Bucillamine
15 Feb 2022 //
GLOBENEWSWIRE
